Category: snoring and apnea

Gozal Named Chair of Child Health 0

Gozal Named Chair of Child Health

David Gozal, MD, MBA, has been named chair of the University of Missouri School of Medicine Department of Child Health, effective Aug. 1, 2018.Leila Kheirandish-Gozal, MD, MSc, has been named vice chair of research for the Department of Child Health, effective Aug. 1, 2018.

Gozal is a leading world expert in the field of sleep medicine. He is known as a pioneer in the study of childhood sleep problems and the relationships between sleep disorders and neurobehavioral, cardiovascular and metabolic disease.

His research has been funded by multiple National Institutes of Health grants and focuses on translational approaches to pediatric sleep disorders, such as childhood obstructive sleep apnea (OSA) and sudden infant death syndrome. An accomplished author and speaker, he has published more than 600 peer-reviewed articles, more than 150 book chapters and reviews, edited three books and has extensively lectured at scientific meetings around the world.

from Sleep Review http://www.sleepreviewmag.com/2018/07/gozal-named-chair-of-child-health/…

Did Medicare Recently Start Denying Claims for Your Patients’ Oral Appliances? Here’s Why. 0

Did Medicare Recently Start Denying Claims for Your Patients’ Oral Appliances? Here’s Why.

A sleep apnea insurance consultant explains how a Centers for Medicare and Medicaid Services system update is impacting dental sleep medicine providers and Medicare beneficiaries—and gives advice on what to do now.

A few months ago, dental sleep medicine providers began receiving denials from the Centers for Medicare and Medicaid Services (CMS) for their patients’ oral appliances. What many long-time clinicians found particularly vexing is these device claims for patients with obstructive sleep apnea were similar to previous claims that had been paid. So what changed?

First, what has not changed: Under the federal regulations detailed at 42 CFR 414.210(f), the reasonable useful lifetime (also known by the abbreviation “RUL”) of durable medical equipment is 5 years. RUL has always applied to same or similar services. Pertaining to obstructive sleep apnea (OSA), Medicare has always considered positive airway pressure devices and oral appliances to be a same or similar service.

What changed is in March of 2018, a system update was applied that no longer allows for claims to be adjudicated as they were in

3D Face Modeling for Sleep Apnea Earns Grant in Western Australia 0

3D Face Modeling for Sleep Apnea Earns Grant in Western Australia

A team of Western Australia researcher is analyzing the facial contours of more than 5,000 Western Australians to identify measurements at various points on the face, head, and neck that could be indicative of obstructive sleep apnea. The team is lead by Sir Charles Gairdner Hospital and University of Western Australia respiratory and sleep physiologist Peter Eastwood, PhD.

With the support of a State Government Medical and Health Research Infrastructure Fund grant, the team has developed computer software that can map the face and morph structural variations, providing a way of predicting the severity of sleep apnea.

Faces being mapped for the study are of hospital sleep clinic patients and participants in Western Australia’s landmark Raine Study. They provide the team with a strong mix of people with and without sleep apnea, in a range of ages.

Eastwood and his team aim to develop a simple, convenient, and noninvasive means of diagnosing serious sleep apnea using a three-dimensional image of a person’s face.

Health Minister Roger Cook says in a release, “This project is an example of some of the

Study Suggests Effectiveness of Blood Test Screening for Sleep Apnea in Adult Males 0

Study Suggests Effectiveness of Blood Test Screening for Sleep Apnea in Adult Males

Positive results of a recent clinical trial suggest that blood tests may offer key benefits in the initial screening for obstructive sleep apnea (OSA). The study, which involved 264 male adult patients from six institutions, revealed that screening for changes in three specific biomarkers may be useful in helping to identify people with OSA. The results of the study were published in the peer-reviewed journal, Nature and Science of Sleep, with the anticipation that use of these objective blood tests will improve screening accuracy and timely diagnosis as well as patient management. Diagnostic medical equipment company Beckman Coulter—whose clinical research department is listed as one of the author’s affiliations—offers this panel of three assays on fully automated platforms in the United States. Hemoglobin A1c (HbA1c) and C-reactive protein (CRP) are chemistry tests on the Synchron and AU systems while erythropoietin (EPO) is on the DxI and Access 2 immunoassay systems.

“The study results demonstrate that sleep apnea induces a characteristic signature cluster of blood biomarker changes,” says principal investigator and lead author Wesley Elon Fleming, MD, diplomate, American Board

Natural Ways To Kiss Snoring Goodbye 0

Natural Ways To Kiss Snoring Goodbye

Snoring has been the bane of existence of many people. It is so bothersome that both the snorers and their spouses lose sleep on a day to day basis without any promise of relief any time soon. Sleep apnea happens to be incurable and people with the condition only receive palliative treatment so the quality of their lives do not deteriorate that much and they get to sleep better too.

When you think about sleep apnea and snoring, you’d likely associate its treatment with surgery or CPAP, both of which aren’t the cheapest option nor the safest or most comfortable either. Fortunately, over the years, there have been newer and more convenient stop snoring products alternatives in the form of sleep apnea mouthpieces. They are fairly easy to use and quite cost-effective too. You don’t have to spend a fortune to get one because many even offer a free trial so you get a feel for what the device feels like before actually paying for it.

In fact, heavy snoring and sleep apnea may be linked to memory and thinking

Switching to Bilevel PAP Saves 56% of Patients from Therapy Termination 0

Switching to Bilevel PAP Saves 56% of Patients from Therapy Termination

A new study reveals that shifting patients who are struggling with adherence to positive airway pressure (PAP) therapy to a more advanced bilevel device in the first 90 days of treatment is an effective tool for achieving adherence in well more than half of such cases.

This research, sponsored by ResMed, was presented at SLEEP 2018.

Patients diagnosed with sleep apnea are usually prescribed a PAP device that provides either continuous (CPAP) or auto-adjusting (APAP) pressure. A bilevel device delivers two distinct pressures, one for inhalation and one for exhalation. Physicians may prescribe bilevel for patients who are pressure intolerant or have continued evidence of apnea at higher pressures.

In this “bilevel rescue” study, ResMed compared 1,496 non-compliant patients (as defined by US Medicare guidelines) who switched to bilevel therapy and found that compliance was achieved by:

  • 58.5% of patients who switched before day 60
  • 54.2% of patients who switched between days 60–90
  • 56.8% of patients overall

“Finding the right mode of therapy made all the difference to those patients who are struggling with initial adherence to therapy,” says ResMed

ResMed Joins Google to Research Sleep Apnea Therapies 0

ResMed Joins Google to Research Sleep Apnea Therapies

Sleep apnoea firm ResMed has joined with Google’s life science division Verily to form a new joint venture studying the health and financial impact of undiagnosed and untreated disease, and find new ways to treat it.

The joint venture will combine ResMed’s expertise in sleep apnoea and Verily’s advanced health data analytics technologies.

As well as assessing the impact of untreated disease on patients’ lives, it will develop software to more efficiently identify, diagnose, treat, and manage patients with sleep apnoea and other breathing related sleep disorders.

Caused by the walls of the throat relaxing and narrowing during sleep and interrupting breathing, the disease affects around 54 million people in the US, and is associated with heart disease, stroke, type 2 diabetes and other life-threatening conditions.

from Sleep Review http://www.sleepreviewmag.com/2018/07/resmed-google-sleep-apnea-therapies/…

Fatigue a Potential Indicator of Overlapping Sleep Apnea and COPD 0

Fatigue a Potential Indicator of Overlapping Sleep Apnea and COPD

A study published in PLOS One finds that patients with overlapping chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) are significantly more fatigued than patients with OSA alone, reports Psychiatry Advisor.

The case-control study enrolled 38 patients with overlap syndrome, 38 patients with OSA only, and 28 healthy control patients through the Alexandra Hospital of Athens. The patients underwent pulmonary function tests, oximetry, and overnight polysomnography and completed the Epworth Sleepiness Scale, Fatigue Severity Scale, and Hospital Anxiety and Depression Scale before and after a 3-month treatment with continuous positive airway pressure (CPAP).

from Sleep Review http://www.sleepreviewmag.com/2018/07/fatigue-a-potential-indicator-of-overlapping-sleep-apnea-and-copd/…

ResMed, Verily to Form Joint Venture to Help Reach People with Untreated Sleep Apnea 0

ResMed, Verily to Form Joint Venture to Help Reach People with Untreated Sleep Apnea

ResMed and Verily, a subsidiary of Alphabet (Google’s parent company) focused on life sciences and healthcare, have entered into an agreement to form a new joint venture.

Combining ResMed’s expertise in sleep apnea and Verily’s advanced health data analytics technologies, the US-based joint venture will study the health and financial impacts of undiagnosed and untreated sleep apnea and develop software solutions that enable healthcare providers to more efficiently identify, diagnose, treat, and manage individuals with sleep apnea and other breathing-related sleep disorders.

“The vast majority of people with sleep apnea don’t realize they have it, and therefore don’t seek accessible, effective treatment to mitigate its effects and long-term health risks,” says ResMed chief medical officer Carlos M. Nunez, MD, in a release. “The combined industry expertise, scalable infrastructure, and data analytics capabilities of ResMed and Verily can unlock meaningful ways to identify these individuals and support their journey to improved sleep, health, and quality of life.”

Jessica Mega, MD, MPH, chief medical and scientific officer at Verily, says, “Approaching a widespread health problem like sleep apnea through collecting, organizing and

Aetna Adds Coverage for Inspire Therapy for the Treatment of Obstructive Sleep Apnea 0

Aetna Adds Coverage for Inspire Therapy for the Treatment of Obstructive Sleep Apnea

Inspire Medical Systems Inc announced that Aetna Inc will provide coverage for the company’s Inspire therapy for obstructive sleep apnea, effective immediately. Aetna’s health plan provides coverage for approximately 22 million members.

“We are very pleased to receive this positive coverage decision from Aetna. We believe this coverage decision is a major milestone and has the potential to facilitate patient and physician access to and interest in Inspire therapy,” says Tim Herbert, president and CEO of Inspire Medical Systems, in a release. “There is a strong body of clinical data supporting Inspire therapy, including the 5-year STAR data, the ADHERE 300-patient registry data and other supportive publications. We believe our growing body of clinical and real-world data will be the basis for further coverage decisions by other major health plans.”

Under its policy, Aetna considers Inspire’s Food and Drug Administration (FDA) approved hypoglossal nerve neurostimulation device to be medically necessary for the treatment of moderate to severe OSA when a number of criteria are met. These include a previous attempt at continuous positive airway pressure (CPAP) treatment and patient selection